Drugs / Recombinant Staphylokinase
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03151993 | Mar 2017 → Mar 2019 | ischemic stroke | Supergene, LLC | Completed | Met primary |
| Phase 43 trials · 1 met primary | ||||||
| Phase 4 | NCT05410925 | Apr 2023 → Dec 2026 expected | ST-elevation myocardial infarction | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT05023681 | Oct 2021 → Aug 2022 | acute myocardial infarction | The First Affiliated Hospital with Nanjing Medical University | Completed | Met primary |
| Phase 4 | NCT05649696 | Oct 2021 → Sep 2023 | ST-elevation myocardial infarction | The First Affiliated Hospital with Nanjing Medical University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant staphylokinase | “This study was to determine whether in patients presenting with ST-segment-elevation myocardial infarction a single bolus recombinant staphylokinase (r-SAK) before timely PCI...” PMID 38258563 ↗ Jan 2024 |
| Known as | Forteplase | “The active substance of Fortelyzin is Forteplase. It's recombinant protein which contains aminoacid sequence of staphylokinase.” NCT03151993 ↗ |
| Known as | r-SAK | “Recombinant SAK (r-SAK) was developed in 1990 by Shanghai Institute of Plant and Biological Physiology.” NCT05023681 ↗ |
| Known as | Recombinant SAK | “Recombinant SAK (r-SAK) was developed in 1990 by Shanghai Institute of Plant and Biological Physiology.” NCT05023681 ↗ |
| Action | Activate | “This complex activates plasminogen trapped in the thrombus.” NCT03151993 ↗ |
| Modality | Protein / enzyme biologic | “It's recombinant protein which contains aminoacid sequence of staphylokinase.” NCT03151993 ↗ |
| Route | Intravenous | “single-bolus intravenous injection of recombinant nonimmunogenic staphylokinase (Fortelyzin)” NCT03151993 ↗ |
| Target | PLG | “which subsequently activates PLG molecules.” NCT05410925 ↗ |